Results 271 to 280 of about 516,295 (311)
Some of the next articles are maybe not open access.
Design of second generation therapeutic recombinant bone morphogenetic proteins
Cytokine & Growth Factor Reviews, 2009Bone morphogenetic proteins (BMPs) are growth factors belonging to the TGF beta super family. To date, more than twenty human BMPs have been identified. Of these, BMP-2 and BMP-7 (also known as osteogenic protein 1 or OP-1) are the only BMPs used clinically.
Moulay Hicham, Alaoui-Ismaili +1 more
openaire +2 more sources
Human cells: New platform for recombinant therapeutic protein production
Protein Expression and Purification, 2012The demand for recombinant therapeutic proteins is significantly increasing. There is a constant need to improve the existing expression systems, and also developing novel approaches to face the therapeutic proteins demands. Human cell lines have emerged as a new and powerful alternative for the production of human therapeutic proteins because this ...
Kamilla, Swiech +2 more
openaire +2 more sources
Applications of capillary electrophoresis in characterizing recombinant protein therapeutics
ELECTROPHORESIS, 2013The use of recombinant protein for therapeutic applications has increased significantly in the last three decades. The heterogeneity of these proteins, often caused by the complex biosynthesis pathways and the subsequent PTMs, poses a challenge for drug characterization to ensure its safety, quality, integrity, and efficacy.
Shuai Sherry, Zhao, David D Y, Chen
openaire +2 more sources
Patents in Therapeutic Recombinant Protein Production Using Mammalian Cells
Recent Patents on Biotechnology, 2014The industrial production of recombinant proteins preferentially requires the generation of stable cell lines expressing proteins in a quick, relatively facile, and a reproducible manner. Different methods are used to insert exogenous DNA into the host cell, and choosing the appropriate producing cell is of paramount importance for the efficient ...
Virginia, Picanco-Castro +3 more
openaire +2 more sources
Therapeutic Use of Recombinant Proteins
1999Cytokines are soluble proteins with diverse biologic and regulatory actions, which are produced by various cell types, including mononuclear cells of the immune system. These proteins act as hormones and can have their effects at sites distant from the point of secretion.
openaire +1 more source
Recombinant Proteins: Evolution to their Therapeutic Potential
Protein & Peptide LettersRecombinant proteins, which are produced using recombinant DNA technology, have transformed the domains of biotechnology and biomedicine by allowing the production of proteins that are often expensive or difficult to obtain from natural sources.
Kalyani R. Thombre +3 more
openaire +1 more source
Therapeutic advances in rheumatology with the use of recombinant proteins
Nature Clinical Practice Rheumatology, 2008Antibody engineering and protein design have led to the creation of a new era of targeted anti-inflammatory therapies in rheumatology. Recombinant DNA technologies have enabled the selection and humanization of specific antibody fragments in order to develop therapeutic reagents of any specificity that can be 'armed' to deliver effective anti ...
Achim, Rothe +2 more
openaire +2 more sources
Production of recombinant protein therapeutics in cultivated mammalian cells
Nature Biotechnology, 2004Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as ...
openaire +2 more sources
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins
Expert Opinion on Drug Discovery, 2009Therapeutic properties of many glycoproteins strongly depend on the composition of their glycans. Most of the current approved glycoproteins are produced in mammalian cell lines, which yield mixture of different glycoforms close to the human one but not fully identical.
Alain, Beck +2 more
openaire +2 more sources
Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins
Current Opinion in Biotechnology, 2018The subcutaneous administration of recombinant therapeutic proteins requires the use of highly concentrated protein formulations to provide the desired dosage in a single injection. These highly concentrated formulations can have very high viscosities, creating challenges in processing (e.g. by ultrafiltration), storage (e.g. enhanced aggregation), and
Youngbin, Baek, Andrew L, Zydney
openaire +2 more sources